173 related articles for article (PubMed ID: 35695486)
1. Serum Expression Levels of Certain miRNAs in Predicting Diagnosis, Prognosis, and Response to Chemotherapy in Malignant Pleural Mesothelioma.
Metintaş M; Ak G; Özbayer C; Boğar F; Metintaş S
Balkan Med J; 2022 Jul; 39(4):246-254. PubMed ID: 35695486
[TBL] [Abstract][Full Text] [Related]
2. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.
De Santi C; Melaiu O; Bonotti A; Cascione L; Di Leva G; Foddis R; Cristaudo A; Lucchi M; Mora M; Truini A; Tironi A; Murer B; Boldorini R; Cipollini M; Gemignani F; Gasparini P; Mutti L; Landi S
Sci Rep; 2017 Jun; 7(1):3140. PubMed ID: 28600498
[TBL] [Abstract][Full Text] [Related]
3. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients.
Matboli M; Shafei AE; Azazy AE; Reda M; El-Khazragy N; Nagy AA; Ali MA; Sobhi M; Abdel-Rahman O
Biomark Med; 2018 Feb; 12(2):129-139. PubMed ID: 29338319
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.
Andersen M; Grauslund M; Ravn J; Sørensen JB; Andersen CB; Santoni-Rugiu E
J Mol Diagn; 2014 Jul; 16(4):418-30. PubMed ID: 24912849
[TBL] [Abstract][Full Text] [Related]
6. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
[TBL] [Abstract][Full Text] [Related]
7. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.
Kirschner MB; Cheng YY; Badrian B; Kao SC; Creaney J; Edelman JJ; Armstrong NJ; Vallely MP; Musk AW; Robinson BW; McCaughan BC; Klebe S; Mutsaers SE; van Zandwijk N; Reid G
J Thorac Oncol; 2012 Jul; 7(7):1184-91. PubMed ID: 22617246
[TBL] [Abstract][Full Text] [Related]
8. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.
Singh A; Bhattacharyya N; Srivastava A; Pruett N; Ripley RT; Schrump DS; Hoang CD
Mol Ther; 2019 Sep; 27(9):1665-1680. PubMed ID: 31227395
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis.
Braza-Boïls A; Salloum-Asfar S; Marí-Alexandre J; Arroyo AB; González-Conejero R; Barceló-Molina M; García-Oms J; Vicente V; Estellés A; Gilabert-Estellés J; Martínez C
Hum Reprod; 2015 Oct; 30(10):2292-302. PubMed ID: 26307093
[TBL] [Abstract][Full Text] [Related]
11. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
[TBL] [Abstract][Full Text] [Related]
12. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
[TBL] [Abstract][Full Text] [Related]
13. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
[TBL] [Abstract][Full Text] [Related]
14. P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma.
Costa C; Indovina P; Mattioli E; Forte IM; Iannuzzi CA; Luzzi L; Bellan C; De Summa S; Bucci E; Di Marzo D; De Feo M; Mutti L; Pentimalli F; Giordano A
Cell Death Dis; 2020 Sep; 11(9):748. PubMed ID: 32929059
[TBL] [Abstract][Full Text] [Related]
15. MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.
Kirschner MB; Cheng YY; Armstrong NJ; Lin RC; Kao SC; Linton A; Klebe S; McCaughan BC; van Zandwijk N; Reid G
Mol Oncol; 2015 Mar; 9(3):715-26. PubMed ID: 25497279
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs dysregulation in human malignant pleural mesothelioma.
Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
[TBL] [Abstract][Full Text] [Related]
17. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
[TBL] [Abstract][Full Text] [Related]
18. Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients.
Lamberti M; Capasso R; Lombardi A; Di Domenico M; Fiorelli A; Feola A; Perna AF; Santini M; Caraglia M; Ingrosso D
PLoS One; 2015; 10(8):e0135331. PubMed ID: 26262875
[TBL] [Abstract][Full Text] [Related]
19. In Silico Transcriptomic Analysis of Wound-Healing-Associated Genes in Malignant Pleural Mesothelioma.
Rouka E; Beltsios E; Goundaroulis D; Vavougios GD; Solenov EI; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212858
[No Abstract] [Full Text] [Related]
20. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
Williams M; Kirschner MB; Cheng YY; Hanh J; Weiss J; Mugridge N; Wright CM; Linton A; Kao SC; Edelman JJ; Vallely MP; McCaughan BC; Cooper W; Klebe S; Lin RC; Brahmbhatt H; MacDiarmid J; van Zandwijk N; Reid G
Oncotarget; 2015 Sep; 6(27):23480-95. PubMed ID: 26125439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
